Jiangsu Vcare Pharmatech Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) targeting moiety via a linker reported to be useful for the treatment of cancer.
Nanjing Mingde New Drug Research Co. Ltd. has divulged pyrimidinone derivatives acting as P2X purinoceptor 3 (P2RX3; P2X3) antagonists reported to be useful for the treatment of cough.
Merck Sharp & Dohme LLC has identified plasma kallikrein (KLKB1) Inhibitors reported to be useful for the treatment of diabetic retinopathy, retinal vein occlusion, hereditary angioedema, diabetes, pancreatitis, intracerebral hemorrhage, nephropathy and inflammatory disorders.
NRG Therapeutics Ltd. has been awarded a grant from Target ALS Foundation to support its discovery program for a treatment for amyotrophic lateral sclerosis (ALS).
Mid-Atlantic Biotherapeutics Inc. and Accelero Biostructures have entered into a research collaboration to identify novel USP30 inhibitors for neurological disorders and other indications.
Essential branched-chain amino acids (BCAA) such as leucine, isoleucine or valine, cannot be synthesized by mammals, making them an obligate part of the diet.
Adaptin Bio has obtained IND clearance from the FDA for APTN-101 in glioblastoma, enabling initiation of a first-in-human phase I trial in patients diagnosed with WHO grade IV malignant glioma.
At the European Federation for Medicinal chemistry and Chemical biology’s International Symposium on Medicinal Chemistry (EFMC-ISMC) held this week in Rome, Novartis Biomedical Research reported the discovery and evaluation of NVP-EVS-459, a low molecular weight folate receptor (FR)-targeting radioconjugate, for the potential treatment and diagnosis of cancer.
RSS
